Skip to main content
    N

    Novartis AG ADR (NVS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $160.21
    -0.29 (-0.18%)

    Market Cap: $303.12B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Novartis AG ADR (NVS) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Novartis AG ADR (NVS) trades at 18.7x trailing earnings and 5.4x sales. Its P/E of 18.7x is above its 5-year median of 14.6x. Its forward P/E is 16.0x. The median P/E across 9 similar companies is 22.5x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 16.9% higher over the next year. Its free cash flow yield is 4.9%.

    MultipleValue
    P/E (trailing)18.7x
    Forward P/E16.0x
    Price to sales5.4x
    Price to book8.2x
    EV/EBITDA15.7x
    Price to FCF20.6x
    EV/FCF23.1x
    PEG3.8
    FCF yield4.9%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 22.2% above 15.3x, its P/S is 31.7% above 4.1x and its P/B is 115.8% above 3.8x.

    MultipleCurrent5-year median10-year median
    P/E18.7x14.6x15.3x
    P/S5.4x4.4x4.1x
    P/B8.2x5.0x3.8x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 12.5x in 2024 to 17.9x in 2019.

    Year endPriceP/EP/SP/B
    2025$137.8715.4x4.8x5.8x
    2024$97.3112.5x3.8x4.4x
    2023$100.9714.8x4.5x4.5x
    2022$90.7214.8x4.0x3.3x
    2021$87.4713.9x3.7x2.9x
    2020$94.4316.3x4.3x3.8x
    2019$94.6917.9x4.5x3.9x
    2018$85.8116.7x4.2x2.5x
    2017$83.9617.3x4.0x2.7x
    2016$72.8415.3x3.5x2.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NVS

    What is NVS's forward P/E ratio?

    Novartis AG ADR has a forward P/E ratio of 16.0x.

    Is NVS stock overvalued?

    GNG's valuation label for NVS is Fairly valued. Its P/E of 18.7x compares with a median of 22.5x across 9 similar companies.

    What is NVS's price to sales ratio?

    Novartis AG ADR has a price to sales ratio of 5.4x.

    What is Novartis AG ADR's average P/E ratio over 5 years?

    Novartis AG ADR's median P/E over the last 5 years is 14.6x, from 60 month-end values through Oct 2026.

    What is NVS's PEG ratio?

    Novartis AG ADR has a PEG ratio of 3.8.